Literature DB >> 10817690

Pharmacokinetics of gentamicin C(1), C(1a), and C(2) in beagles after a single intravenous dose.

N Isoherranen1, E Lavy, S Soback.   

Abstract

The pharmacokinetics of gentamicin C(1), C(2), and C(1a) were studied in six beagles after administration of gentamicin at 4 mg/kg of body weight as a single intravenous bolus dose. Plasma concentrations of the gentamicin components were analyzed with a novel high-performance liquid chromatography method capable of identifying and quantifying each of the components. The pharmacokinetic analysis of the plasma concentration-versus-time data was performed using the noncompartmental approach. The results indicated significant differences in the pharmacokinetic characteristics between the gentamicin components C(1), C(1a), and C(2). The mean residence times of gentamicin C(1), C(1a), and C(2) were 81+/-13, 84+/-12, and 79+/-13 min (mean +/- standard deviation), respectively. The half-lives of the respective components were 64+/-12, 66+/-12 and 63+/-12 min. Clearance (CL) of gentamicin C(1), 4.62+/-0.71 ml min(-1) kg(-1), was significantly higher (P = 0.0156) than CL of gentamicin C(1a), 1.81+/-0.26 ml min(-1) kg(-1), and C(2), 1.82+/-0.25 ml min(-1) kg(-1). Similarly, the volume of distribution at steady state (V(ss)) of gentamicin C(1), 0.36+/-0.04 liter kg(-1), was significantly higher (P = 0.0156) than the V(ss) of gentamicin C(1a), 0.14+/-0.01 liter kg(-1), and C(2), 0.15+/-0.02 liter kg(-1). Tissue binding was considered the most likely cause for the difference. The difference may have clinical and toxicological significance.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10817690      PMCID: PMC89894          DOI: 10.1128/AAC.44.6.1443-1447.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

1.  Determination of gentamicins C(1), C(1a), and C(2) in plasma and urine by HPLC.

Authors:  N Isoherranen; S Soback
Journal:  Clin Chem       Date:  2000-06       Impact factor: 8.327

2.  Assays for therapeutic monitoring and pharmacokinetic investigations of aminoglycosides: quality aspects.

Authors:  L O White
Journal:  Ther Drug Monit       Date:  1998-10       Impact factor: 3.681

3.  Renal clearance and tissue accumulation of gentamicin.

Authors:  J J Schentag; W J Jusko
Journal:  Clin Pharmacol Ther       Date:  1977-09       Impact factor: 6.875

4.  Nephrotoxicity: a comparison in humans of gentamicin and gentamicin C1 administration.

Authors:  A W Forrey; B T Meijsen-Ludwick; M A O'Neill; B M Maxwell; A D Blair; R E Cutler
Journal:  Toxicol Appl Pharmacol       Date:  1978-06       Impact factor: 4.219

5.  Statistical moments in pharmacokinetics.

Authors:  K Yamaoka; T Nakagawa; T Uno
Journal:  J Pharmacokinet Biopharm       Date:  1978-12

6.  Noncompartmental determination of the steady-state volume of distribution.

Authors:  L Z Benet; R L Galeazzi
Journal:  J Pharm Sci       Date:  1979-08       Impact factor: 3.534

7.  Gentamicin disposition and tissue accumulation on multiple dosing.

Authors:  J J Schentag; W J Jusko; J W Vance; T J Cumbo; E Abrutyn; M DeLattre; L M Gerbracht
Journal:  J Pharmacokinet Biopharm       Date:  1977-12

8.  Pharmacokinetics of piperacillin and gentamicin following intravenous administration to dogs.

Authors:  V K Batra; J A Morrison; T R Hoffman
Journal:  J Pharm Sci       Date:  1983-08       Impact factor: 3.534

9.  Variations in gentamicin C1, C1a, C2, and C2a content of some preparations of gentamicin sulphate used clinically as determined by high-performance liquid chromatography.

Authors:  L O White; A Lovering; D S Reeves
Journal:  Ther Drug Monit       Date:  1983       Impact factor: 3.681

10.  Pharmacokinetics of gentamicin in the juvenile dog.

Authors:  J E Riviere; G L Coppoc
Journal:  Am J Vet Res       Date:  1981-09       Impact factor: 1.156

View more
  4 in total

1.  Changes in the distribution of type II transmembrane serine protease, TMPRSS2 and in paracellular permeability in IPEC-J2 cells exposed to oxidative stress.

Authors:  Erzsebet Paszti-Gere; Reka Fanni Barna; Csaba Kovago; Ipoly Szauder; Gabriella Ujhelyi; Csaba Jakab; Nóra Meggyesházi; Andras Szekacs
Journal:  Inflammation       Date:  2015-04       Impact factor: 4.092

2.  Clinical doses of amikacin provide more effective suppression of the human CFTR-G542X stop mutation than gentamicin in a transgenic CF mouse model.

Authors:  Ming Du; Kim M Keeling; Liming Fan; Xiaoli Liu; Timea Kovaçs; Eric Sorscher; David M Bedwell
Journal:  J Mol Med (Berl)       Date:  2006-03-16       Impact factor: 4.599

3.  Rapid and Accurate Detection of Aminoglycoside-Modifying Enzymes and 16S rRNA Methyltransferases by Targeted Liquid Chromatography-Tandem Mass Spectrometry.

Authors:  Dimard E Foudraine; Nikolaos Strepis; Corné H W Klaassen; Merel N Raaphorst; Annelies Verbon; Theo M Luider; Wil H F Goessens; Lennard J M Dekker
Journal:  J Clin Microbiol       Date:  2021-06-18       Impact factor: 5.948

4.  Systematic Review of the Pharmacological Evidence for the Selection of Antimicrobials in Bacterial Infections of the Central Nervous System in Dogs and Cats.

Authors:  Robert Hertzsch; Angelika Richter
Journal:  Front Vet Sci       Date:  2022-01-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.